PharmaCyte Biotech (PMCB) Stock Price
PharmaCyte Biotech Price
Revenue at PharmaCyte Biotech has contracted by 53.3% per year over the past 6 years to 12,160.00 USD. PharmaCyte Biotech's net margin stands at -13,142.3%, down from -1,078.3% several years earlier.
PharmaCyte Biotech stock price
PharmaCyte Biotech business model & stock analysis
Frequently asked questions about PharmaCyte Biotech
6 analysts currently rate the PharmaCyte Biotech stock: 0 recommend buying, 3 holding and 3 selling.
Converted at the current exchange rate, the PharmaCyte Biotech share trades at 0.32 EUR (0.36 USD).
The revenue cannot currently be calculated for PharmaCyte Biotech.
The profit of PharmaCyte Biotech is -19.42 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of PharmaCyte Biotech is currently -0.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PharmaCyte Biotech stock.
The P/S cannot be calculated for PharmaCyte Biotech currently.
The Eulerpool Quality Score for PharmaCyte Biotech is 2/10.
The ISIN of PharmaCyte Biotech is US71715X2036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of PharmaCyte Biotech is A12HVG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of PharmaCyte Biotech is PMCB. The ticker symbol is used to trade PharmaCyte Biotech shares on the stock exchange.
PharmaCyte Biotech stock
PharmaCyte Biotech Peer Group
All fundamentals and in-depth analysis of PharmaCyte Biotech
Our stock analysis for PharmaCyte Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaCyte Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.